GV | Investor Profile

Portfolio companies

GV is on record against 57 companies.

Abacus About.me Acalvio Accent Therapeutics Adagio Therapeutics Adapter Adelphic Mobile Aera Therapeutics Affinia Therapeutics Again Agtonomy Ahana Air Protein Airtime Alector Aledade Alethea Alkira Allara Health Altana AI AltspaceVR Ambition AMP Robotics Anchor Andela AngelList Ankyra Therapeutics Anomali Antiva Biosciences Apptentive Apptimize Appurify Apteligent Arcus Biosciences Arda Therapeutics Areteia Therapeutics Armadin ARMO BioSciences Arrakis Arsanis Artifact Aspen Neuroscience Aspire Health Astrid Attio Autolus Dandelion Energy Dapper Labs Dasient DataFox Datanyze Daydream dbt Labs Decibel Therapeutics Deepset Delighted Delphia Therapeutics

Investment focus

This thesis targets early-stage B2B fintech and proptech startups globally. They invest with a purely financial, non-strategic mandate, aggressively backing competitors. Differentiators include in-house design sprints and ML-driven opportunity scoring.

Related investors

Google VenturesAlso backs Alkira and Dapper Labs and 55 more of the same companies
GVAlso backs Alkira and Dapper Labs and 55 more of the same companies
M.G. SieglerAlso backs Abacus and Anchor and 4 more of the same companies
F-PrimeAlso backs Aera Therapeutics and Affinia Therapeutics
Kapor CapitalAlso backs AngelList and Air Protein

All investors with a sourced record →

Get a deep full report on GV → Get warm-intro paths to GV → See how VCs use MentionFox →